Stereotactic radiosurgery is the mechanically precise stereotactic delivery of a potentially cytostatic, obliterative, or functionally incapacitating single dose of radiation to an imaging-defined target volume while minimizing risk to surrounding tissues. The unique design of stereotactic radiosurgery systems allows small areas of the brain to be treated with high doses of radiation. The sharp falloff of radiation dose prevents brain outside of the target area from receiving deleterious doses of radiation.
History
In the early 1900s, radiation was used primarily by German scientists as a caustic agent, in large single doses, with no selectivity. In the 1920s, French physicians began to exploit the radiation sensitivity of some tissues to achieve a greater therapeutic gain. From the 1940s through the 1960s, British technological developments improved accurate treatment planning and beam direction. Only in the 1970s did we begin to understand the cellular and molecular basis of radiation effects. The first radiosurgical device was created when Swedish neurosurgeon Lars Leksell linked an orthovoltage x-ray tube to a stereotactic frame to treat trigeminal neuralgia. Charged particle radiosurgery later was used by Kjellberg in 1961, many years after the first cyclotron was built at Cambridge, Massachusetts. The first arteriovenous malformation (AVM) was treated in 1965, and the second AVM was treated seven years later.
Linear accelerator units have been used for decades to deliver radiation to the brain. The linear accelerator unit involves a single source of photons emitted from a rotating source. By rotating the source in an arc, the target can be treated while reducing the dose received by the surrounding tissues using multiple fractions (radiation exposures). Linear accelerators were modified to facilitate single-session radiosurgery in the mid-1980s. At some sites, linear accelerator units have been dedicated as radiosurgical treatment units.
The Gamma knife is a unique, dedicated, hospital-based radiosurgery device in which 201 sources of cobalt 60 direct photon radiation to a focal point. The design is excellent for treating targets within the skull, at least down to the level of the foramen magnum. The Leksell stereotactic head frame allows patients to be positioned within the unit with 0.5-mm accuracy. Helmets with 201 collimators of 4, 8, 14, or 18 mm allow conformal shaping of the complex radiation fields that encompass the irregular geometry of the lesion. Between 1967, when it was introduced, and June 1999, the Gamma knife had been used to treat 99,981 patients. Currently there are 51 Gamma knife units in the United States, and 126 units worldwide. Successful radiosurgery requires a multidisciplinary team that includes a neurosurgeon, a radiation oncologist, a medical physicist, a nurse, and an administrator.
Acoustic Neuromas
The goals of acoustic neuroma management include tumor control (radiosurgery) or complete removal (microsurgery), preservation of facial nerve function, and maintenance of "useful" hearing in appropriate patients. A comparison of microsurgery and radiosurgery from 1990 through 1992 revealed that serviceable hearing was preserved in 14% of microsurgery procedures and 75% of Gamma knife procedures. Normal facial function was achieved in 63% of microsurgical procedures and 83% of Gamma knife procedures. Since then, radiosurgery results have improved to the point that normal facial function can be preserved in virtually all patients.
Radiosurgery is performed with a volume acquisition contrast-enhanced MRI in order to localize the target. The treatment of acoustic neuromas at our institution has evolved over the past ten years. Initially, the tumor margin was treated with approximately 18 to 20 Gy, with the center of the tumor receiving up to 40 Gy. The marginal dose has been gradually reduced to 12 to 14 Gy, which has promoted preservation of existing cranial nerve function. We usually treat the tumor margin with 50% of the maximal dose. Between 1987 and 1992, the 10-year tumor control rate was 98%, with normal facial function in 79%, and normal facial sensation in 73% of patients. For patients managed between 1992 and 1997, the control rate was 99%, and the facial nerve morbidity was 1%. Over 60% of patients had a reduction in the volume of their tumor. We have treated 10 patients with intracanalicular acoustic neuromas with 14 Gy or less to the margin and preserved hearing in all patients (Fig. 1) .
Arteriovenous Malformations
The AVM best suited for radiosurgery is not necessarily the same AVM that is best treated by conventional surgery. The ideal candidate for radiosurgery is a patient with a small, deep-seated AVM, not a patient with a larger AVM who was considered unsuitable for microsurgery. In evaluating AVMs, the Spetzler-Martin scale seems best applicable to traditional surgical, not radiosurgical, outcomes. Successful radiosurgery (defined as complete Figure 1 . This intracanalicular acoustic neuroma was detected in a 53-year-old woman with mild hearing loss. The tumor volume was treated with a maximal dose of 26 Gy and a marginal dose of 13 Gy, utilizing five 4-mm isocenters. The plan was designed on the Leksell Gamma Plan shown here (Elekta Instruments, Inc., Atlanta, GA).
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obliteration of the abnormal vasculature) is not as limited as microsurgery by critical locations or the venous drainage pattern. The major shortcoming of radiosurgery for AVMs is the persistent risk of hemorrhage during the latency interval until the AVM is obliterated. Before treatment, the risk of hemorrhage is estimated to be 2% to 4% per year. The risk of hemorrhage is not increased by radiosurgery, but there remains a continued hemorrhage risk during the latent period prior to AVM obliteration.
Proper imaging of a vascular malformation is required for successful radiosurgery. Imaging of AVMs includes a volume acquisition MRI flow study as well as conventional biplane angiography. Both modalities are needed to distinguish the nidus from draining veins and nearby critical structures. Embolization has been evaluated in conjunction with radiosurgery and shown to have a 12.8% morbidity, 1.6% mortality, and 11.8% 1-year recanalization rate. Given the morbidity and incomplete effectiveness of embolization alone, we employ this technique in conjunction with radiosurgery on a selective basis. In particular, in patients with a complaint of severe headache requiring more acute symptom relief, we find that embolization prior to radiosurgery has been quite beneficial.
The radiosurgical dose given to AVMs is a function of the volume and location. The volume, location, and risk are all factors in risk assessment. Giving a higher dose increases the probability of AVM obliteration, but may increase the risk of side effects as well. University investigators reviewed the histology of AVMs that were resected after radiosurgery and found that a dose of greater than 20 Gy was necessary for the desired histological effects (endothelial proliferation, luminal hyperplasia, and thrombosis). In our own experience, AVMs that have not occluded within 3 years of initial radiosurgery generally require additional treatment. The probability of AVM obliteration is approximately 98% for volumes treated with a minimum dose of 25 Gy, and 90% with a minimum dose of 20 Gy. AVMs that are larger than 10 to 15 cm 3 may require irradiation in staged volumes with an interval of 3 to 6 months between procedures (Table 1) .
Meningiomas
Although meningiomas of the falx, convexity, olfactory groove, and lateral sphenoid wing can be treated with radiosurgery, they also can be resected with low morbidity. Meningiomas that are not as easily resected, such as those along the petrous apex or clivus, or those extending into cavernous sinus, often are optimal radiosurgical cases. The steep falloff of radiosurgical dose planning allows these difficult tumors to be treated with marginal doses of 13 to 16 Gy, with a low risk of injury to the associated cranial nerves, pituitary gland, or optic nerve. As for other indications, we generally prescribe a marginal tumor dose that is 50% of the maximal dose.
We have achieved long-term tumor control in 93% of meningiomas, over half of which had been previously resected. Neurological deficits occurred in only 5% of these patients. Overall, 96% of patients surveyed believed that radiosurgery provided a satisfactory outcome for their meningioma. We believe that planned judicious microsurgery, where appropriate, followed by radiosurgery will improve overall clinical outcomes.
Pituitary Tumors
Microsurgery remains the procedure of choice for the rapid treatment of pituitary tumors that are causing mass effect or are endocrine-active. Stereotactic radiosurgery is an effective alternative for patients who do not require urgent decompressive surgery (i.e., who have no optic nerve compression), rapid normalization of endocrine abnormalities, or those who suffer from recurrent tumors despite medical and surgical intervention. The treatment goals for pituitary tumors are control of tumor growth, cessation of abnormal hormone secretion when present, and avoidance of new neurological injury. We have achieved tumor control in 94% of tumors. In our series, cortisol secretion was normalized or reduced in 62.5% of patients with Cushing's disease within 2 years. Growth hormone levels were normalized in 67% of patients with acromegaly, and significantly improved in most of the remaining patients. None of our patients developed pituitary insufficiency as a consequence of radiosurgery.
The greatest risk in treating pituitary lesions with radiosurgery is damage to the optic nerves and optic chiasm. We recommend radiosurgery only for those tumors that are at least 1 to 2 mm away from the optic nerve. The steep radiation falloff of the B unit allows most small pituitary lesions to be treated with 40-to 50-Gy maximal doses (20-to 25-Gy marginal doses), whereas maximal exposure to the optic nerve is less than 8 Gy. Lesions in the sellar area provide an excellent demonstration of the unique radiation falloff pattern for the different Gamma knife units. The B unit has a steeper falloff in the rostral-caudal dimension, whereas the earlier U or A unit has a steeper falloff in the left-right dimension. This differential can be exploited depending on the configuration of the tumor and the surrounding structures. Additionally, some of the unidirectional beams can be blocked selectively to alter the dose distribution (Fig. 2) . 
Brain Metastases
Between 100,000 and 200,000 patients are diagnosed with brain metastases annually in the United States. The management of brain metastases remains a challenge for oncologists, radiation oncologists, and neurosurgeons. Traditional therapy of single metastases has been whole-brain radiation therapy (WBRT), occasionally with a boost to the affected region, or surgery combined with whole-brain radiation. Surgical resection of a solitary metastasis with WBRT has been shown to improve survival compared to WBRT alone. The delayed complications of whole-brain fractionated radiation in long-term survivors include cognitive disorders and other signs of adverse radiation effects.
Stereotactic radiosurgery is changing the long-standing management of brain metastasis. Radiosurgery can achieve many of the same goals as resection (e.g., tumor control, reduced mass effect) and one of the goals of fractionated radiation therapy (the treatment of multiple lesions), and can effectively treat deeply located tumors that are not considered for resection. For patients with a solitary metastasis, radiosurgery may allow WBRT and its potential complications to be avoided. In conjunction with WBRT, radiosurgery can provide rapid improvement in peritumoral edema, local tumor control, and prolonged survival compared with WBRT alone. Radiosurgery provides nearly equivalent tumor control rates for breast, lung, and renal cell carcinoma, as well as melanoma. With control of brain metastasis, the management of systemic disease becomes the survival-limiting factor. Radiosurgery has the additional benefits of 1-to 2-day hospital stays and lower costs.
Other Tumors
Stereotactic radiosurgery can be used effectively to manage other intracranial lesions such as chordomas, chondrosarcomas, certain glial neoplasms, and angiographically occult vascular malformations (AOVM). Stereotactic radiosurgery is an adjuvant therapy, providing a radiation boost to the enhancing component of malignant glial neoplasms. We also have obtained good results in the treatment of juvenile pilocytic astrocytomas in children. AOVMs are treated with radiosurgery after a second symptomatic hemorrhage utilizing the same dose algorithm applied to AVMs. Although the baseline risk of hemorrhage for AOVMs is approximately 1% annually, the natural history of AOVMs suggests that patients with a second symptomatic hemorrhage have an increased tendency toward hemorrhage (Ͼ30% annually).
Functional Radiosurgery
Lars Leksell originally designed the Gamma knife in 1967 to create functional lesions for the treatment of psychiatric disorders. Today, radiosurgery is used to treat trigeminal neuralgia, essential tremor, Parkinsonian tremor, and, occasionally, psychiatric disorders such as obsessive compulsive disorder. Several groups have attempted radiosurgical pallidotomy for Parkinson's disease, but the results generally have been inferior to the results of radiofrequency lesions. Radiosurgical thalamotomy (ventral intermediolateral thalamic nucleus) is performed with anatomical MRI localization. Tremor is improved in most patients after a latency interval of 2 to 6 months (Fig. 3) .
Criticisms of Radiosurgery
Radiosurgery initially was viewed as an inferior alternative to traditional neurosurgical techniques. Common criticisms of radiosurgery included the following: the tumor is not removed; there is no rapid reduction in mass effect; and future surgery will be more difficult. Additionally, patients may have a false sense of cure. It is true that the tumors often are not eliminated, but the goal of radiosurgery is tumor control, not extirpation. A rapid reduction in mass effect often is not required, and edema , has its steepest falloff in the rostral-caudal direction, minimizing the dose received by the optic nerve. The 50%, 30%, and 20% isodose lines are shown here. The tumor margin was treated with 17 Gy, with a maximal dose of 34 Gy. The optic chiasm was exposed to less than 8 Gy.
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often is significantly reduced following radiosurgery. There are no substantive data to support the criticism that radiosurgery complicates future operations. One study of arteriovenous malformations that were resected after radiosurgery found that they were less vascular and easier to remove. One report noted that eight of thirteen acoustic tumors resected after radiosurgery appeared to be more difficult to resect than the average acoustic tumor, although five of these eight had undergone prior resection as well. Finally, patient misconceptions are addressed with education and long-term follow-up. We obtain MRI scans at 6, 12, 24, 48, and 96 months following treatment of benign lesions, and every 3 years or so thereafter. We obtain more frequent follow-up for patients with malignant diseases.
Complications of Radiosurgery
Although there are almost no immediate complications of radiosurgery, complications do occur. Such problems include small patches of alopecia for lesions adjacent to the scalp, brain edema, adverse radiation effects, neurological deficits, and failure to achieve the intended goal. The risk of complications is a function of the tissue volume being treated, the dose delivered, the location, and prior radiation treatments (Table 2) .
There is no absolute maximal tolerated dose that can be tolerated by important neuroanatomical structures such as the optic nerve, but our general guidelines are included in Table 2 . The maximum volume treated also depends on the location, the radiosurgical indication, and prior therapies. Large volumes are more easily treated in the frontal lobe than in the brainstem. In general, treating volumes larger than 10 cm 3 increases the risk of complications. Flickinger et al found that complications after AVM radiosurgery varied considerably with location and the volume of tissue receiving greater than 12 Gy. Locations, in order of increasing risk for radiosurgery complications, were frontal, temporal, intraventricular, parietal, cerebellar, corpus callosum, occipital, medulla, thalamus, basal ganglia, and pons/midbrain. Oncologic indications may dictate the use of higher doses, accepting higher risk, than non-oncological indications.
The risk-benefit ratio weighs heavily in favor of radiosurgery. In our experience treating over 3500 cases with the Gamma knife, the risk of significant sustained morbidity is less than 3%. The chance of successful tumor control is greater than 90% for most lesions. Long-term results now demonstrate that radiosurgery is an important therapeutic alternative for patients who are ineligible for surgery due to deep-seated lesions or serious medical conditions, or for patients who would like to avoid the risks of microsurgery. Figure 3 . This MR image shows a radiosurgical thalamotomy performed 6 months earlier for Parkinsonian tremor. The patient reported a significant improvement in contralateral tremor beginning 2 weeks after treatment.
